Crystal's MCW Coder Hub🧬 ICD-10-CM H35.3210 — Exudative AMD, Right Eye, Stage Unspecified
Last-Resort Code AND Category Shift Alert
Two important flags on H35.3210:
1. Last-Resort Code: H35.3210 is a valid, billable 7-character code — but it is a documentation deficiency indicator. The wet AMD activity status (active CNV? inactive CNV? inactive scar?) is almost always determinable from the OCT report, fluorescein angiography, or clinical documentation. Exhaust all record sources and submit a CDI query before defaulting to stage unspecified.
2. Category Shift: You have crossed from the nonexudative (dry) AMD family (H35.31x) into the exudative (wet) AMD family (H35.32x). These are fundamentally different disease processes — wet AMD involves pathologic choroidal neovascularization (CNV) and is treated with anti-VEGF intravitreal injections, not AREDS2 supplementation or GA-targeting drugs (Syfovre/Izervay). The staging system, treatment drugs, J-codes, and clinical management are entirely distinct from everything in the H35.31x notes.
Billable Code Confirmed
H35.3210 is a valid, billable 7-character ICD-10-CM code for FY2025. [web:126] All seven characters are present:
H35(category) +.3(degeneration of macula) +2(exudative) +1(right eye) +0(stage unspecified). No additional characters required — this code will process on a claim.
Non-Billable Parent Codes — Do Not Submit These
- ❌
H35.321— 6-character header — missing activity status character- ❌
H35.32— 5-character header — missing laterality AND activity status Always submit H35.3210 (all 7 characters) when stage is truly unspecified.
🔍 Code Description
H35.3210 classifies exudative (wet) age-related macular degeneration of the right eye, stage unspecified — used when choroidal neovascularization has been diagnosed in the right eye in the context of AMD, but the current activity status of the CNV (active leaking, inactive quiescent, or end-stage inactive scar) cannot be determined from available documentation at the time of coding.1
Wet AMD is defined by the pathologic growth of choroidal new blood vessels (CNV) through Bruch’s membrane into the subretinal or sub-RPE space. These fragile new vessels leak fluid and blood, causing rapid and severe central vision loss — the hallmark clinical emergency of AMD. Unlike dry AMD, which progresses over years, wet AMD can cause vision loss measurable in days to weeks from symptom onset. The activity status (7th character) reflects whether the CNV is currently active and leaking (H35.3211), has been treated to quiescence but vessels remain (H35.3212), or has progressed to a permanent disciform fibrovascular scar (H35.3213).
🌳 H35.32x — Wet AMD Code Family Overview
Entering the Exudative AMD Family — Learn This Structure Before H35.3211-3213 Notes
This is the first note in the H35.32x (wet AMD) series. The complete right-eye wet AMD staging family:
H35.32 Exudative AMD ❌ Non-billable header
│
└── H35.321 Right Eye ❌ Non-billable header
│
├── H35.3210 Right eye, stage UNSPECIFIED ◀ THIS CODE ⚠️ LAST RESORT
├── H35.3211 Right eye, ACTIVE CNV ✅ Most common — active wet AMD
├── H35.3212 Right eye, INACTIVE CNV ✅ Treated/quiescent wet AMD
└── H35.3213 Right eye, INACTIVE SCAR ✅ End-stage disciform scar
Type 1 vs. Type 2 CNV — A Nuance That Affects H35.3210 vs H35.3211 Assignment
CNV in wet AMD is classified by its anatomic location relative to the RPE:
- Type 1 CNV (occult/sub-RPE) — vessels beneath the RPE; may be present without visible fluid on standard OCT; detected on OCT-A or FA; may represent “quiescent” CNV — does this code as H35.3212 or H35.3211? Query the physician.
- Type 2 CNV (classic/subretinal) — vessels break through the RPE into the subretinal space; almost always associated with visible fluid = H35.3211 active
- Type 3 CNV (retinal angiomatous proliferation/RAP) — intraretinal origin; strongly associated with fluid = H35.3211 active
When the record documents Type 1 CNV without fluid — and the physician has not labeled it active or inactive — this is a legitimate scenario for H35.3210 + CDI query before assuming H35.3212.
✅ Includes
The following limited scenarios map to H35.3210 — right eye, exudative AMD, stage unspecified:1
- Exudative AMD, right eye — CNV activity status not documented
- Wet AMD, right eye NOS — after full record review, activity status indeterminate
- Neovascular AMD, right eye — stage unknown at time of coding
- Exudative AMD, right eye — pending fluorescein angiography results before activity status determination
"Wet AMD" and "Neovascular AMD" Both Map Here
The clinical terms “wet AMD” and “neovascular AMD” are used interchangeably by physicians and refer to the same condition: exudative AMD with CNV. Both map to the H35.32x family. When either term appears without activity status (active/inactive/scar), assign H35.3210 interim and query for specificity.
❌ Excludes
Excludes 21
| Code Range | Description | Action |
|---|---|---|
| E08.311-E08.359 | Drug/chemical-induced DM with diabetic retinopathy | Use diabetic retinopathy code when DM is the etiology |
| E10.311-E10.359 | Type 1 DM with diabetic retinopathy | Use diabetic retinopathy code when DM is the etiology |
| E11.311-E11.359 | Type 2 DM with diabetic retinopathy | Use diabetic retinopathy code when DM is the etiology |
| E13.311-E13.359 | Other specified DM with diabetic retinopathy | Use diabetic retinopathy code when DM is the etiology |
Diabetic CNV vs. AMD CNV — Etiology Matters
CNV can occur in the context of diabetic eye disease (proliferative diabetic retinopathy with CNV) OR in the context of AMD. These are etiologically distinct and code differently. When a diabetic patient develops CNV, the physician’s documentation of the etiology is critical — AMD-related CNV in a diabetic patient codes to H35.32xx, while DR-related CNV codes to the appropriate E11.3xx combination code. Do not assume AMD etiology simply because the patient is elderly — query if the etiology is not explicit.
💊 Anti-VEGF Treatment Overview — The H35.32x Drug Landscape
Anti-VEGF Drugs Are the Treatment Backbone for All H35.32xx Codes
Every anti-VEGF drug listed below links to the intravitreal injection CPT code 67028-RT plus the drug-specific J-code. The ICD-10-CM diagnosis codes H35.3210-H35.3213 all support anti-VEGF billing — though H35.3210 (stage unspecified) may face higher payer scrutiny than stage-specific codes. The stage-specific code preferred by payers for anti-VEGF coverage is almost always H35.3211 (active CNV) — stage unspecified may trigger prior authorization delays.
Current Anti-VEGF Drugs and J-Codes (FY2025)
| Drug | Generic | HCPCS | Units | Dose | Mechanism |
|---|---|---|---|---|---|
| Vabysmo | Faricimab-svoa | J2777 | 60 units per 6mg dose | 6mg/0.05mL | Anti-VEGF-A + anti-Ang-2 bispecific [web:131] |
| Eylea (2mg) | Aflibercept 2mg | J0178 | Per current CMS guidance | 2mg/0.05mL | VEGF-A + PlGF trap [web:128] |
| Eylea HD (8mg) | Aflibercept 8mg | J0177 | Per current CMS guidance | 8mg/0.1mL | VEGF-A + PlGF trap — extended interval [web:128] |
| Lucentis | Ranibizumab | J2778 | 5 units per 0.5mg dose | 0.5mg/0.05mL | Anti-VEGF-A Fab [web:130] |
| Byooviz | Ranibizumab-nuna | Q5126 | Biosimilar — verify | 0.5mg | Ranibizumab biosimilar |
| Beovu | Brolucizumab-dbll | J0179 | Per current CMS guidance | 6mg/0.05mL | Anti-VEGF-A scFv |
| Susvimo | Ranibizumab implant | J2779 | Per implant | 100mg/mL reservoir | Port delivery system — continuous release [web:136] |
Vabysmo (J2777) — Bill 60 Units
Vabysmo (faricimab-svoa) is increasingly the first-line anti-VEGF choice for wet AMD due to its bispecific mechanism (anti-VEGF-A AND anti-Ang-2) and the potential for extended treatment intervals (up to every 4 months after loading doses in some patients). Bill J2777 × 60 units per 6mg injection. Always use 67028-RT as the accompanying procedure code.
JZ Modifier — Required by CMS for Zero Drug Wastage
Beginning July 1, 2023, CMS requires the JZ modifier on drug claims when there are no discarded units of the administered drug. The JZ modifier indicates the entire vial/dose was administered with no wastage. Failure to append JZ (or the JW modifier for discarded units) on anti-VEGF drug J-codes may result in claim denial or audit exposure. Verify your practice’s JZ/JW modifier workflow for every anti-VEGF injection claim.
Anti-VEGF Treatment Dosing Schedules — Loading and Maintenance
| Phase | Vabysmo | Eylea (2mg) | Eylea HD (8mg) | Lucentis | Beovu |
|---|---|---|---|---|---|
| Loading | Monthly × 4 | Monthly × 3 | Monthly × 3 | Monthly × 3 | Monthly × 3 |
| Maintenance | Q8-16 weeks (treat & extend) | Q8 weeks (fixed) or PRN | Q12-16 weeks (extended) | Q4 weeks (fixed) or PRN | Q12 weeks |
| Max extended interval | Every 4 months | Every 2 months (standard) | Every 16 weeks | Monthly most common | Every 12 weeks |
Treat-and-Extend vs. Fixed vs. PRN — Affects Claim Frequency
The anti-VEGF dosing strategy affects how many injection claims will be submitted annually:
- Fixed interval (Eylea monthly or bimonthly): predictable, high-frequency claim volume
- PRN (as needed): injection only when reactivation detected on OCT; lower claim volume but requires monthly monitoring OCTs
- Treat-and-extend (T&E): interval extended when dry, shortened when fluid returns; most common current strategy for Vabysmo and Eylea HD
When coding the monitoring visits between injections, the diagnosis should reflect the current activity status — H35.3212 (inactive, monitoring between injections under T&E) or H35.3211 (if fluid reactivated at that visit).
💰 HCC Risk Adjustment (CMS-HCC v28)
| Field | Detail |
|---|---|
| CMS-HCC Model Version | v28 (2024-2025 Implementation) |
| HCC Assignment | ❌ Not Mapped |
| HCC Category | N/A |
| RAF Coefficient | 0.000 |
H35.3210 carries no direct HCC weight — consistent across all H35.32x codes.
Wet AMD Encounter = High-Yield Comorbidity Capture Opportunity
The anti-VEGF injection visit is often a monthly encounter — one of the most frequent physician touchpoints for elderly Medicare patients. Each injection visit is an opportunity to document and code qualifying comorbidities. At every H35.32xx injection encounter, sweep for:
Comorbidity HCC (v28) Priority Type 2 DM HCC 18 Highest — AMD and DM share vascular risk pathway Heart failure HCC 85 High — anti-VEGF systemic absorption; cardiac risk monitoring relevant Atrial fibrillation HCC 96 High — anticoagulation status affects injection bleeding risk CAD HCC 85 Moderate CKD Stage 3-5 HCC 137 Moderate Depression F32.x Vision loss + injection burden → high depression risk Vision impairment H54.xx Separately codeable when VA criteria met
🏥 MS-DRG Assignment
MDC 02 — Diseases and Disorders of the Eye
| DRG | Title | Est. Relative Weight* |
|---|---|---|
| DRG 124 | Other Disorders of the Eye with MCC | ~0.95-1.15 |
| DRG 125 | Other Disorders of the Eye with CC | ~0.70-0.90 |
| DRG 126 | Other Disorders of the Eye without CC/MCC | ~0.50-0.70 |
*Verify against IPPS FY2025 Final Rule tables.
Wet AMD in the Inpatient Setting
Like dry AMD, wet AMD is managed almost exclusively in the outpatient setting. In the inpatient setting, H35.3210 appears as an additional diagnosis — typically in elderly patients admitted for cardiovascular events, falls, or surgical procedures. The key inpatient coding consideration: anti-VEGF injection regimens in progress at the time of admission should be documented by the attending/hospitalist, and the ophthalmology team should be consulted to maintain the injection schedule or assess for reactivation if the admission extends beyond the patient’s injection interval.
🔗 Related ICD-10-CM Codes
The Complete Wet AMD Right-Eye Family
| Code | Stage | CNV Active? | Fluid? | Anti-VEGF? | Priority |
|---|---|---|---|---|---|
| H35.3210 | Unspecified ⚠️ | ? | ? | Query | Last resort |
| H35.3211 | Active CNV | ✅ Yes | ✅ Yes | ✅ Urgent | Most common wet AMD code |
| H35.3212 | Inactive CNV | Quiescent | ❌ No | Continue/extend | Post-treatment monitoring |
| H35.3213 | Inactive scar | Scar | ❌ No | Often stopped | End-stage disciform |
Bilateral and Left-Eye Equivalents
| Code | Description |
|---|---|
| H35.3220 | Exudative AMD, left eye, stage unspecified |
| H35.3230 | Exudative AMD, bilateral, stage unspecified |
| H35.3231 | Exudative AMD, bilateral, active CNV |
| H35.3290 | Exudative AMD, unspecified eye, stage unspecified ⚠️⚠️ |
Concurrent Dry AMD — Dual Coding
| Code | Description | When to Co-Code |
|---|---|---|
| H35.3113 | Nonexudative AMD, right eye, advanced no subfoveal | When dry AMD GA co-exists in same eye |
| H35.3114 | Nonexudative AMD, right eye, advanced subfoveal | When subfoveal GA co-exists with CNV in same eye |
Commonly Co-Coded
| Code | Description | Relationship |
|---|---|---|
| H54.11x | Blindness, right eye | If VA ≤20/200 — separately codeable |
| H54.8 | Legal blindness | When legal blindness criteria met |
| H53.131 | Sudden visual loss, right eye | Acute presentation — initial wet AMD symptom |
| Z82.1 | Family history of blindness | Risk factor documentation |
🛠️ CPT / HCPCS — Wet AMD Anti-VEGF Injection Claim Template
This Template Applies to H35.3210-H35.3213 — Wet AMD Right Eye All Stages
The claim structure for anti-VEGF injections is the same regardless of which H35.321x code is used. The diagnosis code may differ visit-to-visit (active on one visit → inactive the next) but the CPT + J-code billing pattern is consistent.
Standard Anti-VEGF Injection Visit
| Type | Code | Description | Notes |
|---|---|---|---|
| Procedure | 67028-RT | Intravitreal injection of pharmacological agent, right eye | Always required with drug J-code |
| Drug (Vabysmo) | J2777 × 60 | Faricimab-svoa 6mg | Most common current choice [web:131] |
| Drug (Eylea 2mg) | J0178 × units | Aflibercept 2mg | Verify current unit count with CMS |
| Drug (Eylea HD 8mg) | J0177 × units | Aflibercept 8mg | Extended interval — verify units |
| Drug (Lucentis) | J2778 × 5 | Ranibizumab 0.5mg | 5 units per injection [web:130] |
| Drug (Beovu) | J0179 × units | Brolucizumab 6mg | Verify current unit count |
| Modifier (no wastage) | JZ | Zero drug discarded | Required since July 1, 2023 [web:130] |
| Monitoring | 92134 | OCT posterior segment | Required at each injection visit — fluid measurement |
Monitoring Visit (No Injection — PRN or Between T&E Intervals)
| Type | Code | Description | Notes |
|---|---|---|---|
| Exam | 92014 | Comprehensive ophthalmological exam, established | |
| OCT | 92134 | OCT posterior segment | Fluid surveillance — primary tool |
| FA | 92235 | Fluorescein angiography | When reactivation suspected or CNV characterization needed |
| OCT-A | 92134 or payer-specific | OCT angiography | CNV activity assessment — verify payer coverage |
OCT at Every Wet AMD Visit — Active or Monitoring — Bill It
92134 is separately billable at every wet AMD encounter — injection visit OR monitoring visit. OCT is the primary tool that determines whether the CNV is active (fluid present → H35.3211) or inactive (no fluid → H35.3212) at that encounter, directly driving the ICD-10-CM code for that visit. It is not bundled with 67028 under NCCI. Document and bill it every time.
📊 Wet AMD Staging — The Three Billable Stages
Before understanding when to use H35.3210 (unspecified), you must know what you’re trying to resolve it to:
| Code | Stage | CNV Status | OCT Findings | Typical Treatment | Typical VA |
|---|---|---|---|---|---|
| H35.3210 | Unspecified ⚠️ | Unknown | Unknown | Cannot determine | Unknown |
| H35.3211 | Active CNV | ✅ Active / leaking | Subretinal fluid, intraretinal fluid, PED, new hemorrhage | Anti-VEGF injection — monthly loading or PRN/T&E | Rapidly declining if untreated |
| H35.3212 | Inactive CNV | CNV present but quiescent | Fluid resolved, fibrosis beginning, CNV membrane visible but not leaking | Monitor — extend injection interval or observe | Stable or improving |
| H35.3213 | Inactive scar | Disciform scar | Subretinal fibrosis / disciform scar replacing CNV membrane — no active fluid | No active treatment — low vision management | Severely reduced — usually permanent |
The Injection Decision IS the Stage Documentation
In practice, the most reliable clinical indicator of wet AMD stage is the physician’s injection decision at today’s visit:
Injected today → Active CNV → H35.3211 (treatment required = active disease)
Extended interval / deferred injection — fluid resolved → Inactive CNV → H35.3212
Discontinued treatment — scar present, no fluid, no hope of VA recovery → Inactive scar → H35.3213
If you know whether the patient received an injection today and why, you almost always know the CNV activity status — and therefore have no need for H35.3210. The injection schedule is your first clue before you even read the OCT report.
🔍 When H35.3210 vs. Stage-Specific Wet AMD Codes
| Situation | Correct Action | Code |
|---|---|---|
| OCT report shows subretinal fluid + physician injected today | Active CNV — no query needed | H35.3211 |
| OCT report shows resolved fluid + interval extended + no injection today | Inactive CNV — no query needed | H35.3212 |
| Record documents “disciform scar” or “end-stage wet AMD” | Inactive scar — no query needed | H35.3213 |
| Record says “wet AMD” — no other detail, OCT report not yet available | CDI query + H35.3210 interim | H35.3210 interim |
| Anti-VEGF injections ongoing but no current-visit OCT documentation | H35.3211 likely — query to confirm activity status | Query → H35.3211 or H35.3212 |
| Patient treated in the past, no current treatment, no recent imaging | CDI query — inactive CNV vs. scar? | Query → H35.3212 or H35.3213 |
| Legacy record — “neovascular AMD” — no imaging available | H35.3210 acceptable | H35.3210 |
H35.3210 + Anti-VEGF J-Code on the Same Claim = Red Flag
A claim pairing H35.3210 (stage unspecified) with an anti-VEGF drug J-code (J2778, J2777, J0178, J0179, etc.) is a significant coding inconsistency. Anti-VEGF injections are indicated for active CNV — if the patient is receiving an injection, the diagnosis should almost certainly be H35.3211 (active CNV), not unspecified. Payer prepayment edits increasingly flag this pairing. Resolve before submission:
📋 Clinical Overview — Wet AMD Background
Pathophysiology — Why Wet AMD Is Different From Dry
In exudative AMD, the complement-mediated RPE dysfunction that drives dry AMD reaches a tipping point where VEGF (vascular endothelial growth factor) is upregulated, stimulating choroidal neovascularization (CNV) — the growth of abnormal new blood vessels from the choroidal circulation through Bruch’s membrane into the subretinal or sub-RPE space. Unlike the years-long progression of dry AMD, CNV causes rapid, acute central vision loss through:2
-
Fluid leakage — CNV vessels are fragile and leaky; subretinal and intraretinal fluid accumulates rapidly, distorting and destroying photoreceptors
-
Subretinal hemorrhage — CNV vessels bleed, causing acute sudden vision loss
-
Photoreceptor detachment — fluid accumulation physically separates photoreceptors from their RPE support
-
Fibrovascular scar formation — untreated or inadequately treated CNV progresses to disciform fibrosis, permanently replacing the foveal architecture
This is why wet AMD is an ophthalmologic urgency — a patient who calls with sudden new metamorphopsia (Amsler grid distortion) or acute central vision loss requires same-day or next-day evaluation and OCT, not a scheduled appointment weeks away.
The Conversion Event — From Dry to Wet
Approximately 10-15% of AMD patients develop wet AMD, yet wet AMD accounts for approximately 90% of severe AMD-related vision loss due to its acute onset and rapid progression if untreated. Wet AMD most commonly develops from:
-
Intermediate dry AMD (H35.3112) converting to active CNV
-
Advanced dry AMD with GA (H35.3113/H35.3114) developing concurrent CNV in the same eye
When conversion is documented:
-
Retire the dry AMD code for the affected eye (H35.311x) and assign H35.3211 (active CNV) — or retain the dry AMD code alongside H35.3211 if GA is also present concurrently (see H35.3114 notes)
-
Begin anti-VEGF treatment documentation — []-RT + drug J-code
Anti-VEGF — The Treatment Revolution
Anti-VEGF therapy transformed wet AMD from a near-certain path to legal blindness into a manageable condition where vision can be stabilized or improved in a majority of patients treated promptly. All approved anti-VEGF agents are administered as intravitreal injections ([]-RT for right eye), delivering drug directly to the vitreous cavity adjacent to the retina.
💊 Anti-VEGF Drug Reference — All Current Agents
This Is the Most CPT/HCPCS-Dense Coding Area in Ophthalmology
Wet AMD encounters — especially active CNV (H35.3211) — generate more billable codes per visit than almost any other outpatient ophthalmology scenario. Every injection visit includes the injection CPT, the drug J-code, an OCT, an exam, and often angiography. Coding accuracy on the drug J-code, unit count, and laterality modifier is critical because these are high-cost claims reviewed by every major payer.
FDA-Approved Anti-VEGF Agents — Wet AMD (Current as of FY2025/2026)
| Drug | Generic | HCPCS | Units to Bill | Dose | Manufacturer |
|---|---|---|---|---|---|
| Eylea | Aflibercept 2mg | J0178 | 1 unit per 2mg injection | 2mg/0.05mL | Regeneron |
| Eylea HD | Aflibercept 8mg | J0179 | 1 unit per 8mg injection | 8mg/0.07mL | Regeneron |
| Vabysmo | Faricimab-svoa | J2777 | 60 units per 6mg injection | 6mg/0.05mL | Genentech |
| Lucentis | Ranibizumab 0.5mg | J2778 | 5 units per 0.5mg injection | 0.5mg/0.05mL | Genentech |
| Beovu | Brolucizumab-dbll | J0179* | Verify current code | 6mg/0.05mL | Novartis |
| Susvimo | Ranibizumab implant | C9399 or per payer | Port delivery system — NOT intravitreal injection | 100mg/mL reservoir | Genentech |
| Byooviz | Ranibizumab-nuno (biosimilar) | J2778 | 5 units per 0.5mg | Biosimilar to Lucentis | Samsung Bioepis |
| Cimerli | Ranibizumab-eqrn (biosimilar) | J2778 | 5 units per 0.5mg | Biosimilar to Lucentis | Coherus |
| Yesafili | Aflibercept-jbvf (biosimilar) | Q5155 or per payer | Per aflibercept dose | Biosimilar to Eylea | Bioeq |
| Bevacizumab | Bevacizumab (off-label, compounded) | J9035 | Per dose — highly variable | Off-label repackaged | Multiple compounders |
Verify Current HCPCS Codes — This Space Changes Rapidly
The anti-VEGF J-code landscape has expanded significantly with biosimilar approvals since 2023. Always verify the current HCPCS code and unit count against the CMS HCPCS quarterly update and the manufacturer’s billing guide before submitting any anti-VEGF claim. Biosimilar codes in particular are being assigned on a rolling basis — a Q-code (temporary) may have been replaced by a permanent J-code.
The JZ Modifier — Required Since July 1, 2023
Beginning July 1, 2023, CMS requires the JZ modifier on all anti-VEGF drug claims to indicate that no drug was discarded (entire vial used for one patient). If drug IS discarded, the JW modifier is used instead to report the discarded amount. Failing to append JZ or JW to anti-VEGF J-codes on or after July 1, 2023 will result in claim denial.
How to apply:
J2777-JZ— Vabysmo, no waste (full 6mg dose administered, no discard)
J0178-JZ— Eylea 2mg, no waste
J2778-JW— Lucentis, drug discarded (partial dose used; report waste separately)
Treatment Regimens — Loading Phase vs. Maintenance
| Phase | Description | Typical Schedule | H35.32xx Stage During |
|---|
| Phase | Description | Typical Schedule | H35.32xx Stage During |
|---|---|---|---|
| Loading phase | Initial 3 monthly injections to rapidly suppress CNV | Monthly × 3 | H35.3211 (active CNV) |
| PRN (as needed) | Inject only when OCT shows recurrent fluid | Monthly monitoring; inject if fluid present | H35.3211 if fluid active; H35.3212 if dry |
| Treat and Extend (T&E) | Extend injection interval by 2-week increments when fluid resolves | Variable — up to every 16 weeks | H35.3211 if any fluid; H35.3212 if fully dry |
| Maintenance / extended | Stable, fluid-free patient — long intervals | Every 12-16 weeks | H35.3212 if truly inactive |
| Discontinuation | Treatment stopped — scar present | PRN monitoring only | H35.3213 if disciform scar |
T&E Protocol and Code Assignment — The "Dry" Visit Question
Under the Treat and Extend protocol, a patient may present with no fluid on OCT at an injection visit — yet still receive an injection to maintain the extended interval. Is this H35.3211 or H35.3212? Per coding guidelines and clinical consensus: if the physician’s rationale for injection is prevention of recurrence under an established T&E protocol, and fluid is absent today, the CNV is technically inactive at this visit → H35.3212 is more accurate. However, if the physician documents “treated to maintain disease control” without specifying inactive status, a CDI query may be appropriate. Many retina practices default to H35.3211 for all injection visits — this is a common area of coding variability worth discussing with your retina physicians for consistent documentation.
💊 Coding Scenarios
Scenario 1 — Emergency Wet AMD Presentation — Activity Status Clear (Outpatient)
Clinical Vignette: A 73-year-old female with known dry AMD (H35.3112 right eye, intermediate, last coded 3 months ago) presents urgently reporting sudden central distortion and visual blur, right eye, onset 5 days ago. VA: 20/200 OD (was 20/30 at last visit). OCT: large subretinal fluid collection with CNV, right eye. FA confirms classic CNV with active leakage. Physician documents: “New wet AMD conversion, right eye — active CNV — urgent anti-VEGF initiation.” Vabysmo injected today.
CPT / HCPCS:
- 67028-RT — Intravitreal injection, right eye
- J2777 × 60 units — Faricimab-svoa 6mg (Vabysmo) — JZ modifier appended (no wastage)
- 92134 — OCT posterior segment (subretinal fluid confirmation, CNV measurement)
- 92235 — Fluorescein angiography (CNV characterization, leakage pattern)
- 92014 — Comprehensive ophthalmological exam (urgent evaluation, VA decline, treatment discussion)
ICD-10-CM:
- H35.3211 — Exudative AMD, right eye, active CNV (not H35.3210 — active CNV with fluid is explicitly documented → use stage-specific code directly)
- H53.131 — Sudden visual loss, right eye (5-day sudden onset — separately codeable as the presenting symptom)
H35.3210 Not Needed Here — Activity Status Crystal Clear
Scenario 2 — Wet AMD History in Outside Records — Activity Status Unknown (Outpatient)
Clinical Vignette: A new patient transfers care to your retina practice. Brings a summary from prior ophthalmologist: “History of wet AMD, right eye — last injection approximately 4 months ago.” No prior OCT images or visit notes available. Today’s visit is a new patient evaluation; OCT is ordered but results are still pending at time of coding.
ICD-10-CM (Interim — OCT Pending):
- H35.3210 — Exudative AMD, right eye, stage unspecified *(appropriate interim —Perfect — full wet AMD code family and all current anti-VEGF J-codes confirmed.
STOP — Category Shift Alert: You Are Now in Wet AMD Territory
H35.3210 belongs to the H35.32x — Exudative (Wet) AMD family — a completely different disease process, staging system, and treatment paradigm from the H35.31x dry AMD codes. Key orientation points:
Feature Dry AMD (H35.31x) Wet AMD (H35.32x) Pathology Drusen, RPE atrophy, geographic atrophy Choroidal neovascularization (CNV) Staging logic Early / Intermediate / Advanced (no subfoveal) / Advanced (subfoveal) Active CNV / Inactive CNV / Inactive Scar Primary treatment AREDS2, Syfovre, Izervay Anti-VEGF intravitreal injections Urgency Monitored over months-years Urgent — active CNV = ophthalmologic emergency Vision trajectory Slow, progressive loss over years Rapid loss within weeks if untreated Everything from the H35.311x notes — AREDS2 indications, Beckman staging, drusen criteria — does NOT apply here. The wet AMD family operates on its own clinical and coding logic entirely.
Billable Code Confirmed
H35.3210 is a valid, billable 7-character ICD-10-CM code for FY2025. All seven characters present:
H35(category) +.3(degeneration of macula) +2(exudative) +1(right eye) +0(stage unspecified). Processes on a claim — but is a last-resort documentation deficiency code.[3]
Non-Billable Parent Codes
- ❌
H35.321— 6-character header — missing staging character- ❌
H35.32— 5-character header — missing laterality AND staging Always submit H35.3210 (all 7 characters) if stage is genuinely indeterminate.
The Wet AMD 7th Character Is NOT Compatible With Dry AMD
This is the most important orientation point when moving from H35.311x notes to H35.321x notes. The 7th character meanings are completely different:
A patient with wet AMD does NOT have an “early,” “intermediate,” or “advanced” stage in the H35.321x coding system. The staging axis for wet AMD is CNV activity status — a treatment-response metric, not a severity ladder in the traditional sense.
7th Character In Dry AMD (H35.311x) In Wet AMD (H35.321x) 0Stage unspecified ⚠️ Stage unspecified ⚠️ 1Early dry stage Active CNV ✅ 2Intermediate dry stage Inactive CNV ✅ 3Advanced, no subfoveal GA Inactive scar ✅ 4Advanced, subfoveal GA N/A — no 4th stage in wet AMD
Scenario 3 — CDI Query Language for Wet AMD Stage
Sample Query:
“The medical record documents exudative (wet) AMD of the right eye. To assign the most accurate ICD-10-CM code, please specify the current CNV activity status of the right eye at this encounter:
— Active choroidal neovascularization (CNV actively leaking — subretinal or intraretinal fluid present on OCT or angiography)
— Inactive choroidal neovascularization (CNV present but quiescent — fluid resolved on treatment)
— Inactive scar (disciform scar — fibrotic end-stage, no active CNV)
— Unable to determine
— Other: _“
⚠️ Coding Pitfalls and Tips
| Pitfall or Tip | |
|---|---|
| ❌ | Never use dry AMD staging logic (early/intermediate/advanced) for wet AMD — the 7th character means something completely different in H35.321x |
| ❌ | Never submit H35.321 (6-character) — non-billable header — H35.3210 (7 characters) is required if stage truly unspecified |
| ❌ | Never pair H35.3210 with an anti-VEGF injection J-code without resolving to H35.3211 — active injection = active CNV = H35.3211 in virtually all cases |
| ❌ | Never use H35.3210 as a default — OCT report almost always resolves the stage |
| ✅ | Read the OCT report first — subretinal fluid = active CNV = H35.3211; no fluid, scar = H35.3213; no fluid, CNV present but quiescent = H35.3212 |
| ✅ | Use the injection decision as a stage clue — injected today = most likely active CNV H35.3211 |
| ✅ | Append JZ or JW modifier to all anti-VEGF J-codes — mandatory since July 1, 2023; claims will deny without it |
| ✅ | Verify current J-codes before every claim — biosimilar additions and code revisions occur quarterly; do not rely on memorized codes |
| ✅ | Use H35.3210 as interim only — always flag for correction when OCT or query response becomes available |
| ✅ | When dry AMD and wet AMD co-exist in the same eye — code both (H35.3114 + H35.3211) as concurrent conditions |
📚 Sources
1. CMS/NCHS. ICD-10-CM Official Guidelines for Coding and Reporting, FY2025. Tabular List — H35.32 Exudative AMD staging structure; Excludes 2 notations; General Coding Guidelines Section I.B.5 — Unspecified codes.
2. MD Clarity. “ICD Diagnosis Code H35.3211: What It Is & When to Use.” Wet AMD pathophysiology — active CNV mechanism, subretinal fluid, rapid vision loss.
3. Genentech Access Solutions. VABYSMO Wet AMD Billing Codes. J2777, 60 units per 6mg dose; []-RT; JZ modifier requirement; H35.3210-H35.3211 diagnosis code reference.
4. Genentech/Lucentis. Lucentis Wet AMD Billing Codes. J2778, 5 units per 0.5mg; JZ modifier requirement.
5. CMS. Billing and Coding: Aflibercept (EYLEA®) — Article A53387. J0178 — 1 unit per 2mg injection; Q5155 update for biosimilar.
6. GenHealth.ai. “H35.3213 ICD10CM — Exudative AMD, right eye, with inactive scar.” Full H35.321x family structure; H35.3210 confirmed billable.
7. Outsource Strategies International. “Coding Macular Degeneration.” H35.3211-H35.3213 code descriptions.
8. AAPC. ICD-10 Code H35.3211 — Exudative AMD, right eye, with active CNV. Confirmed billable FY2025.